Please login to the form below

Deal Watch table for November 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during November 2013.

For an indepth analysis of these deals, read 'Pharma deals during November 2013'

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Viropharm / Shire	Acquisition	Orphan drugs including Cinryze for prophylactic treatment of hereditary angioedema	4,200
Santarus / Salix	Acquisition	Portfolio of approved products in GI, diabetes and Hyperlipidemia	2,600
Algeta / Bayer	Acquisition	Buys out deal for Xofigo radiotherapeutic for prostate cancer	2,400
Pfizer / Lilly	Co-development	Shared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain	1,800
Novartis / Grifols	Acquisition	Novartis divestment of its blood transfusion testing unit	1,675
Paladin / Endo Health	Acquisition	Portfolio includes products in attention deficit hyperactivity disorder, pain, urology and allergy	1,600
immatics / Roche	R&D and commercialisation	IMA942 tumour-associated peptide cancer vaccine candidates in NSCLC and prostate cancer	1,017
Patheon / Royal DSM and JLL Partners	Merger and acquisition	DSM and JLL Partners (private equity) acquire Patheon and merge it with DSM's CMO Pharmaceutical Products Division in a jointly owned Newco	582
Polyphor / Roche	Licence	POL7080 which targets Pseudomonas aeruginosa, completed phase I	548
Cytori/Lorem Vascular	Licence	Cell therapy for CVS, diabetes, and renal disease includes equity purchase	531
Vital Signs/ CareFusion	Acquisition	Vital Signs is the respiratory care and anesthesiology product manufacturer division of GE Healthcare	500
Clovis / Servier	Licence	Servier licenses lucitanib excluding China, Japan and the US	475
Egalet /Shionogi	Licence	Oral abuse-deterrent hydrocodone opioid products includes an equity purchase	425
EOS /Clovis	Acquisition	Lucitanib for FGF aberrant breast cancer	420
BeiGene / Merck Serono	Co-development	Expansion of collaboration to include BeiGene 290 for cancer	232
Cell Therapeutics / Baxter	Licence	JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase	172
Vertex / Janssen	Royalty sale	Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica	152
Calidus / Amicus	Acquisition	Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease	130
Evotec /Janssen	R&D collaboration	Target AD collaboration to identify novel therapies for Alzheimer's	125
Merck & Co / Akorn	Product acquisition	US rights to AzaSite, Cosopt, Cosopt PF ophthalmic products	52.8